Rexahn Pharma

Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Rexahn Pharmaceuticals Inc. shares REXN, +0.00% rose more than 7% in premarket trade Tuesday, after the company said it has hired Oppenheimer & Co.

Rexahn Pharma shares rally more than 7% on news to explore strategic options

Rexahn Pharmaceuticals, Inc. (NYSE: RNN) shares are advancing to a two-month high following an  announcement  from the company regarding a Chinese licensing deal.

China Licensing Deal Sends Nanocap Rexahn Pharma Rocketing Higher

News for Rexahn Pharma Stock (RNN)